Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Karine Dahan,Hanna Debiec,Emmanuelle Plaisier,Marine Cachanado,Alexandra Rousseau,Laura Wakselman,Pierre-Antoine Michel,Fabrice Mihout,Bertrand Dussol,Marie Matignon,Christiane Mousson,Tabassome Simon,Pierre Ronco,GEMRITUX Study Group,Vincent Audard,Pierre Bataille,Yvon Berland,Jean-Jacques Boffa,Nicolas Bouvier,Laura Braun,Frank Bridoux,Stéphane Burtey,Déborah Chaintreuil,Cindy Castrale,Gabriel Choukroun,Christian Combe,Eric Daugas,Michel Delahousse,Ariane Duval-Sabatier,Marie Essig,Isabelle Etienne,Hélène François,Denis Fouque,Denis Glotz,Michel Godin,Bertrand Gondouin,Morgane Gosselin,Maryvonne Hourmant,Aurélie Hummel,Corinne Isnard-Bagnis,Charlotte Jouzel,Bruno Hurault de Ligny,Alexandre Karras,Thomas Kofman,Philippe Lang,Sandrine Lemoine,Anne-Sophie Librez Verhoeven,Rafik Mesbah,Laurent Mesnard,Bruno Moulin,Jean-Noël Ottavioli,Marie-Noelle Péraldi,Evangeline Pillebout,Claire Pouteil-Noble,Philippe Rieu,Claire Rigothier,Jean-Philippe Ryckelynck,Djillali Sahali,Zaara Soltani,Marc Souid,Thomas Stehlé,Maxime Touzot,Pierre Trolliet,Philippe Vanhille,Céline Lebas,David Verhelst,Cecile Vigneau,Laurence Vrigneaud,François Vrtosvnik
DOI: https://doi.org/10.1681/ASN.2016040449
Abstract:Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals (NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m2 intravenous rituximab on days 1 and 8 (n=37) or NIAT alone (n=38). Median times to last follow-up were 17.0 (interquartile range, 12.5-24.0) months and 17.0 (interquartile range, 13.0-23.0) months in NIAT-rituximab and NIAT groups, respectively. Primary outcome was a combined end point of complete or partial remission of proteinuria at 6 months. At month 6, 13 (35.1%; 95% confidence interval [95% CI], 19.7 to 50.5) patients in the NIAT-rituximab group and eight (21.1%; 95% CI, 8.1 to 34.0) patients in the NIAT group achieved remission (P=0.21). Rates of antiphospholipase A2 receptor antibody (anti-PLA2R-Ab) depletion in NIAT-rituximab and NIAT groups were 14 of 25 (56%) and one of 23 (4.3%) patients at month 3 (P<0.001) and 13 of 26 (50%) and three of 25 (12%) patients at month 6 (P=0.004), respectively. Eight serious adverse events occurred in each group. During the observational phase, remission rates before change of assigned treatment were 24 of 37 (64.9%) and 13 of 38 (34.2%) patients in NIAT-rituximab and NIAT groups, respectively (P<0.01). Positive effect of rituximab on proteinuria remission occurred after 6 months. These data suggest that PLA2R-Ab levels are early markers of rituximab effect and that addition of rituximab to NIAT does not affect safety.